Welcome to our dedicated page for PHH SEC filings (Ticker: PHH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The PHH SEC filings page for Park Ha Biological Technology Co., Ltd. provides access to the company’s regulatory disclosures as a foreign private issuer whose ordinary shares have traded on the Nasdaq Capital Market. Park Ha Biological Technology Co., Ltd. has indicated that it files annual reports under cover of Form 20-F, and it furnishes current reports on Form 6-K to report significant events and updates to investors.
Through these filings, readers can review documents such as operating and financial review and prospects in connection with unaudited consolidated financial statements for specified interim periods, as well as the underlying financial statements themselves. These materials help explain the company’s performance in its core activities of developing a private skincare label, direct skincare product sales, and franchise alliance promotions under the "Park Ha" brand.
Park Ha Biological Technology Co., Ltd. also uses Form 6-K to disclose corporate governance and capital structure actions. Examples include notices and results of annual general meetings, shareholder approvals for a dual-class share capital structure with Class A and Class B ordinary shares carrying different voting rights, amendments and restatements of the memorandum and articles of association, and authorization of a share consolidation within a defined ratio range. Filings further document shareholder ratification of the company’s independent registered public accounting firm.
Listing-related developments are another key component of PHH filings. The company has reported Nasdaq notifications regarding non-compliance with the minimum closing bid price requirement and the minimum market value of listed securities requirement, outlining the applicable compliance periods, conditions for regaining compliance, and potential consequences if compliance is not achieved. In addition, Park Ha Biological Technology Co., Ltd. has filed a Form 6-K describing the change of its Nasdaq trading symbol from "PHH" to "BYAH," noting that the change is intended to avoid confusion with a previously delisted company that used the same symbol and that its ordinary shares will continue to be listed on Nasdaq.
On Stock Titan, these SEC filings are updated in near real time from the EDGAR system, and AI-powered summaries help explain the key points of lengthy documents such as 20-F annual reports and 6-K current reports. Users can quickly understand the implications of changes in share structure, listing status notifications, financial disclosures, and other regulatory events without reading every page of the underlying filings.
Park Ha Biological Technology Co., Ltd. announced a change of trading symbol for its ordinary shares to BYAH, from PHH. The Company anticipates the new ticker will become effective on the Nasdaq Stock Market at the open of trading on Monday, October 28, 2025.
The Company also issued a press release about the ticker symbol change, furnished as Exhibit 99.1.
Park Ha Biological Technology Co., Ltd. reports that shareholders approved several major corporate actions at the 2025 annual general meeting. Holders of 21,872,753 ordinary shares, out of 33,874,403 issued and outstanding as of the September 8, 2025 record date, voted, satisfying quorum requirements.
Shareholders approved a redesignation of the company’s capital so it is authorized to issue 15,000,000,000 ordinary shares of par value US$0.00002 each, split into 12,000,000,000 Class A shares with 1 vote per share and 3,000,000,000 Class B shares with 20 votes per share. The existing 33,874,403 ordinary shares were reclassified as Class A, and 19,050,000 Class A shares held by Xiaoqiu Zhang will be surrendered for nil consideration in exchange for 19,050,000 Class B shares.
Shareholders also approved new amended and restated constitutional documents to reflect the dual-class structure and streamline meeting requirements, authorized a share consolidation at a ratio between 1-for-5 and 1-for-30 to be set later by the board, and ratified the appointment of WWC P.C. as independent auditor for the fiscal year ending October 31, 2025.
Park Ha Biological Technology Co., Ltd. filed a Form 6-K related to its 2025 annual general meeting. The company is furnishing a formal notice of the 2025 annual general meeting dated September 12, 2025 and a form of proxy card to be mailed to shareholders. These materials are intended to inform shareholders about the meeting and enable them to vote, either in person or by proxy.
Park Ha Biological Technology Co., Ltd. has received two Nasdaq deficiency notices, one for its share price and one for its market value. Nasdaq notified the company that its ordinary shares failed to meet the minimum closing bid price of $1 per share for 30 consecutive business days, triggering non-compliance with Nasdaq Listing Rule 5550(a)(2). The company has 180 days, until March 2, 2026, to regain compliance by having its bid price at or above $1 for at least ten consecutive trading days.
On the same date, Nasdaq also informed the company that its Market Value of Listed Securities had remained below the required $35 million for 30 consecutive business days under Listing Rule 5550(b)(2). The company has until March 2, 2026 to restore MVLS at or above $35 million for at least ten consecutive business days, or its securities may face delisting, subject to potential additional cure periods and appeal rights. The company states it intends to take reasonable measures and monitor its status but cannot assure it will regain or maintain compliance.
Park Ha Biological Technology Co., Ltd. reported that independent director Mr. Da Yang resigned from the board, effective August 25, 2025. The company states that his resignation was not due to any disagreement with its operations, policies, or procedures, indicating this is presented as a non-controversial board change. The report is signed on behalf of the company by Chief Executive Officer and Chairperson of the Board, Xiaoqiu Zhang.
Park Ha Biological Technology Co., Ltd. (symbol: PHH) filed a Form S-8 on 10 July 2025 to register an additional 4,500,000 ordinary shares for issuance under its Amended and Restated 2025 Share Incentive Plan. The amendment lifts the plan’s total share reserve to 7,500,000 shares, incorporating a prior S-8 filed on 3 March 2025. The filing is strictly administrative, containing standard exhibits such as the legal opinion, the amended plan, auditor consent, and filing-fee table. No financial statements, earnings data, or transaction details are provided; the document’s primary purpose is to facilitate future equity awards to employees, directors, and other eligible participants.
FAQ
What is the current stock price of PHH (PHH)?
What is the market cap of PHH (PHH)?
